Neuromuscular diseases

Patient identification can be challenging because many neuromuscular diseases are rare and genetically diverse, with patients often dispersed across broad geographic regions. Delayed diagnosis, varying disease progression and strict eligibility criteria can further limit the pool of potential participants. Successful neuromuscular trial recruitment and enrollment often depend on early planning, access to specialized clinical sites, and effective engagement with the neuromuscular community.

Digital technologies are increasingly being used to enhance data collection and improve the participant experience in neuromuscular clinical trials. Wearable devices, electronic clinical outcome assessments (eCOAs), telehealth visits, remote monitoring and digital biomarkers can provide more continuous, real-world insights while reducing the need for frequent site visits. These approaches may also help improve patient compliance and capture disease progression more effectively.

Gene therapy studies involve unique scientific and operational considerations, including genetic testing, specialized product handling, immunogenicity monitoring and long-term safety follow-up. Because these therapies may produce durable or permanent effects, studies often require extended patient monitoring and careful planning around manufacturing, logistics and regulatory requirements. Selecting appropriate clinical sites and standardized procedures is also critical to study success.

Recent advancements in muscular dystrophy therapy include gene therapies, exon-skipping treatments, gene editing research and therapies designed to improve muscle function or slow disease progression. Clinical trials are also evaluating novel RNA-based therapies, combination approaches and treatments targeting additional forms of muscular dystrophy beyond Duchenne. As the therapeutic landscape evolves, clinical studies continue to play a critical role in evaluating long-term safety, efficacy and functional outcomes.

Gene therapy has shown promising results for some patients with Duchenne muscular dystrophy (DMD), particularly through the delivery of micro-dystrophin genes designed to restore partial dystrophin protein production. While early clinical studies have demonstrated encouraging biological and functional outcomes, researchers continue to evaluate long-term durability, safety and clinical benefit. Ongoing clinical trials are helping to refine patient selection, optimize dosing strategies and better understand long-term treatment effects.

ALS clinical trials face several challenges due to the disease's rapid progression and variability between patients. Recruiting participants early in the disease course, selecting clinically meaningful endpoints, minimizing patient burden and maintaining participant retention throughout the study are all important considerations. Trial designs increasingly seek to balance rigorous data collection with approaches that improve accessibility and reduce demands on patients and caregivers.

ALS clinical research continues to evolve as new therapeutic approaches are evaluated, including gene-targeted therapies, antisense oligonucleotides, stem cell therapies and treatments aimed at slowing disease progression. Advances in biomarkers, digital monitoring and wearable technologies, along with adaptive trial designs, are also helping researchers collect more robust data and evaluate therapies more efficiently. These innovations are improving the design and conduct of ALS clinical trials while supporting the development of potential new treatment options.